Unimolecular GLP1R/GIPR dual agonists not only amplify the metabolic benefits of GLP-1 therapies but may also reduce common side effects, offering an effective strategy for managing obesity and T2D-related conditions (57, 58). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.